Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Abatacept

Brand: Orencia┬«
NICE TA: 
Indication: LMMG RA Biologic Pathway (Subcutaneous monotherapy in patients unable to take methotrexate, as a 3rd line biologic treatment)
Disease category: Musculoskeletal and joint diseases
Commissioning responsibility: CCG
PbR excluded: Yes

Background

Abatacept subcutaneous monotherapy is recommended only in patients who are unable to take methotrexate, who have moved through the commissioned pathway to 3rd line biologic treatment, and who experience an adverse reaction to the initial loading dose of tocilizumab monotherapy, or in whom tocilizumab is contraindicated, or who have already received tocilizumab as a 1st or 2nd line biologic agent.

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Red

Red

Red